CG Oncology, Inc. Common stock

CG Oncology, Inc. Common stock

CGON·NASDAQ

$54.42

-0.85%
HealthcareBiotechnology

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

At a Glance

Live Snapshot
Market Cap$4.80B
EPS-2.0800
P/E Ratio-26.16
Earnings Date08/07/2026

cgon

Other Current Liabilities

Last Annual Value

24.21M

3-Year CAGR

419%

5-Year CAGR

84%

10-Year CAGR

36%

CG Oncology, Inc. Common stock

CG Oncology, Inc. Common stock Competitors Analysis of Other Current Liabilities

CGON · NASDAQ
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
24.21M
253.7%84.5%N/A 
129.23M
11.1%26.7%6.6%
183.00M
8.6%N/A17.1%
23.18M
10.6%N/AN/A
117.50M
N/A361.7%N/A
27.01M
67.1%79.5%N/A
CELC logo
Celcuity Inc.
NASDAQ:CELC
37.69M
74.4%140.0%N/A
1.00M
145.0%-59.1%N/A
CG Oncology, Inc. Common stock

CG Oncology, Inc. Common stock Fair Value Envelope

CGON · NASDAQ

Our analysis suggests that CGON has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $54.42, this represents a potential HIDDEN relative to our calculated worth for CG Oncology, Inc. Common stock.

Intrinsic Value
Current Price: $54.42